v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Crohn's and Colitis Foundation Agreement [Member]
Stock Purchase Agreement [Member]
Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Crohn's and Colitis Foundation Agreement [Member]
Common Stock [Member]
Stock Purchase Agreement [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Crohn's and Colitis Foundation Agreement [Member]
Additional Paid-in Capital [Member]
Stock Purchase Agreement [Member]
Accumulated Deficit [Member]
Balance (in shares) at Dec. 31, 2024       200,000 2,768,646            
Balance at Dec. 31, 2024 $ 7,492     $ 2 $ 27     $ 143,407     $ (135,944)
Net loss (5,014)                   (5,014)
Stock-based compensation expense and related charges 138             138      
Issuance of common stock in connection under Employee Stock Purchase Plan (in Shares)         4,601            
Issuance of common stock in connection under Employee Stock Purchase Plan 3             3      
Issuance of common stock in connection with exercise of warrants (in shares)         2,027,000            
Issuance of common stock in connection with exercise of warrants 1       $ 21     (20)      
Balance (in shares) at Jun. 30, 2025       200,000 4,800,247            
Balance at Jun. 30, 2025 2,620     $ 2 $ 48     143,528     (140,958)
Balance (in shares) at Mar. 31, 2025       200,000 4,396,646            
Balance at Mar. 31, 2025 5,331     $ 2 $ 43     143,460     (138,174)
Net loss (2,784)                   (2,784)
Stock-based compensation expense and related charges 69             69      
Issuance of common stock in connection under Employee Stock Purchase Plan (in Shares)         4,601            
Issuance of common stock in connection under Employee Stock Purchase Plan 3             3      
Issuance of common stock in connection with exercise of warrants (in shares)         399,000            
Issuance of common stock in connection with exercise of warrants 1       $ 5     (4)      
Balance (in shares) at Jun. 30, 2025       200,000 4,800,247            
Balance at Jun. 30, 2025 2,620     $ 2 $ 48     143,528     (140,958)
Balance (in shares) at Dec. 31, 2025       200,000 159,444,017            
Balance at Dec. 31, 2025 129,380     $ 2 $ 1,594     280,509     (152,725)
Balance (in shares) at Mar. 31, 2026       200,000 167,421,702            
Balance at Mar. 31, 2026 127,362     $ 2 $ 1,674     288,011     (162,325)
Balance (in shares) at Dec. 31, 2025       200,000 159,444,017            
Balance at Dec. 31, 2025 129,380     $ 2 $ 1,594     280,509     (152,725)
Net loss (20,174)                   (20,174)
Stock-based compensation expense and related charges 9,082             9,082      
Issuance of common stock to vendors (in shares)         10,000            
Issuance of common stock for vesting of restricted stock units (in shares)         29,798            
Issuance of common stock in connection under Employee Stock Purchase Plan (in Shares)         13,031            
Issuance of common stock in connection under Employee Stock Purchase Plan 20             20      
Issuance of common stock in connection with exercise of warrants (in shares)         12,369,753            
Issuance of common stock in connection with exercise of warrants 155       $ 123     32      
Issuance of stock during period, Shares           191,717 1,536,885        
Issuance of stock during period   $ 313 $ 2,972     $ 2 $ 16   $ 311 $ 2,956  
Balance (in shares) at Jun. 30, 2026       200,000 173,595,201            
Balance at Jun. 30, 2026 121,748     $ 2 $ 1,735     292,910     (172,899)
Balance (in shares) at Mar. 31, 2026       200,000 167,421,702            
Balance at Mar. 31, 2026 127,362     $ 2 $ 1,674     288,011     (162,325)
Net loss (10,574)                   (10,574)
Stock-based compensation expense and related charges 4,785             4,785      
Issuance of common stock to vendors (in shares)         5,000            
Issuance of common stock in connection under Employee Stock Purchase Plan (in Shares)         13,031            
Issuance of common stock in connection under Employee Stock Purchase Plan 20             20      
Issuance of common stock in connection with exercise of warrants (in shares)         6,155,468            
Issuance of common stock in connection with exercise of warrants 155       $ 61     94      
Balance (in shares) at Jun. 30, 2026       200,000 173,595,201            
Balance at Jun. 30, 2026 $ 121,748     $ 2 $ 1,735     $ 292,910     $ (172,899)